Category - Developments

Developments

Clene presents positive Phase 2 interim ALS efficacy data

Clene (NASDAQ:CLNN) presented positive blinded interim efficacy data from its ongoing Phase 2 RESCUE-ALS clinical trial evaluating the efficacy, safety, pharmacokinetics and pharmacodynamics of CNM-Au8 in the treatment...

May 12, 2021

Developments

RNA Disease Diagnostics inaugural board of directors and advisory board meet

Closely-held RNA Disease Diagnostics held an inaugural joint meeting of its board of directors and advisory board, which will work alongside the leadership team to advance the company’s...

May 11, 2021

Developments

IntelGenx shareholders approve atai Life Sciences investment

Shareholders at a virtual annual meeting of IntelGenx Technologies (TSXV:IGX; OTCQB:IGXT) approved atai Life Sciences AG’s investment in IntelGenx. Under the accord, atai initially will acquire an approximate 25%...

May 11, 2021

Developments

RNA Disease Diagnostics stepwise protocol for molecular diagnosis of COVID-19 published in Nature Protocols

RNA Disease Diagnostics’ stepwise protocol for an RNA-extraction-free nano-amplified colorimetric test for COVID-19 was published in Nature Protocols. The test uses a unique dual-pronged molecular...

May 6, 2021

Developments

Profound Medical, Akumin in U.S. multi-center commercial pact for TULSA-PRO

Profound Medical (NASDAQ:PROF; TSX:PRN) signed a multi-site imaging center agreement for its TULSA-PRO device with Akumin (NASDAQ, TSX:AKU), a leading provider of freestanding, fixed-site outpatient diagnostic imaging...

May 6, 2021

Developments

Hepion Pharma completes patient recruitment in Phase 2a AMBITION trial of CRV431 in advanced NASH

Hepion Pharmaceuticals (NASDAQ:HEPA) completed recruitment for its Phase 2a AMBITION clinical trial, with all non-alcoholic steatohepatitis (NASH) patients in the 225 mg CRV431 dosing cohort now enrolled. After...

May 6, 2021

Developments

Hepion Pharma presents machine learning “learn and confirm” modeling strategy at NASH Congress

Hepion Pharmaceuticals (NASDAQ:HEPA) SVP of clinical pharmacology and analytics, Dr. Patrick Mayo, gave a virtual presentation entitled, “CRV431 – From Benchtop to Bedside Clinical Development” at the 4th Global NASH...

April 29, 2021

Developments

Seelos receives positive EMA orphan drug opinion for SLS-005 in ALS

Seelos Therapeutics (NASDAQ:SEEL) received a positive opinion on European orphan drug designation for SLS-005 in amyotrophic lateral sclerosis (ALS) from the EMA committee for orphan medicinal products. The positive...

April 20, 2021

Developments

Ripple Therapeutics treats first patient in DME, RVO Phase 2 trial

The first patient has been treated in Ripple Therapeutics’ RIPPLE-1 Phase 2 trial evaluating IBE-814 IVT, a proprietary intravitreal dexamethasone implant targeting inflammatory retinal diseases. RIPPLE-1 is a single...

April 20, 2021

Developments

MiMedx announces last patient visits in 3 late-stage musculoskeletal trials

MiMedx Group (NASDAQ:MDXG) announced that the last patients have completed their last clinical visits in two late-stage IND trials: Phase 3 studies of AmnioFix injectable as a potential treatment for plantar fasciitis...

April 19, 2021

Category - Developments

Subscribe